  In this article we have conducted a reanalysis of the phase III aducanumab
(ADU) summary statistics announced by Biogen, in particular the result of the
Clinical Dementia Rating-Sum of Boxes (CDR-SB). The results showed that the
evidence on the efficacy of the drug is very low and a more clearer view of the
results of clinical trials are presented in the Bayesian framework that can be
useful for future development and research in the field.
